Source comparison
The Structural Difference: Kisspeptin-54 vs Kisspeptin-10
Kisspeptin-54 is the full endogenous neuropeptide. 54 amino acids starting from the N-terminus, encoded by the KISS1 gene on chromosome 1q32. Kisspeptin-10 consists of amino acids 45–54 (the C-terminal decapeptide) and represents the minimum sequence required
This comparison does not assign a generated winner or score.
- Kisspeptin-54 is the full endogenous neuropeptide. 54 amino acids starting from the N-terminus, encoded by the KISS1 gene on chromosome 1q32. Kisspeptin-10 consists of amino acids 45–54 (the C-terminal decapeptide) and represents the minimum sequence required for full GPR54 receptor activation. The receptor binding site. The arginine-phenylalanine (RF-amide) motif at the C-terminus. Is identical in both. Proteolytic enzymes in plasma (primarily aminopeptidases and endopeptidases) cleave kisspeptin-54 progressively from the N-terminus, producing intermediate fragments (kisspeptin-14, kisspeptin-13) before reaching the stable kisspeptin-10 core.
- Research conducted at Imperial College London demonstrated that kisspeptin-10 binds the GPR54 receptor with an EC50 (half-maximal effective concentration) of 1.3 nM. Statistically indistinguishable from kisspeptin-54's 1.1 nM. The functional outcome. Pulsatile GnRH secretion from hypothalamic neurons. Is identical at equimolar concentrations. The 44 additional amino acids in kisspeptin-54 do not enhance receptor affinity; they increase molecular weight (5.4 kDa vs 1.3 kDa) and vulnerability to degradation. In vivo studies show kisspeptin-54 has a plasma half-life of approximately 28 minutes in humans, while kisspeptin-10 extends to 90 minutes under the same conditions. The fragment's compactness sterically hinders protease access to the critical RF-amide binding domain.
- From a synthesis standpoint, producing kisspeptin-10 via solid-phase peptide synthesis (SPPS) requires fewer coupling cycles, lower reagent volumes, and simplified purification. Translating to 60–70% cost reduction per milligram compared to full-length kisspeptin-54. Real Peptides uses small-batch SPPS with HPLC verification at each synthesis stage to ensure exact amino-acid sequencing in every kisspeptin-10 vial. The tighter the sequence fidelity, the more predictable the receptor kinetics in downstream assays.